Kepu Imaging Group Secures Nearly RMB 1 Billion in Series A Funding to Expand Third-Party Imaging Centers and Advance High-End Medical Imaging Equipment R&D

Recently, VCBeat learned that Kaipu Imaging Group, a leading domestic full-chain service provider in the medical imaging industry, has officially announced the completion of its Series A financing round, raising nearly RMB 100 million. This round was exclusively invested by Yueyin Medical Fund.

Mr. Sun Zhaochang, founder of Kaipu Imaging Group, stated: “China’s medical imaging market is vast, with many regions still representing untapped markets. Over the next three years, the Group will”We will prioritize the nationwide deployment of independent medical imaging centers to maximize patient service experience. Meanwhile, the Group will continue to intensify its R&D efforts and recruit top scientists globally, focusing on high-end 512-slice CT manufacturing and artificial intelligence, with the aim of becoming a world-leading provider of medical imaging equipment and services.。”

KePu Imaging Group operates two core business segments: the R&D and manufacturing of high-end medical imaging equipment, and third-party medical imaging centers., committed to building a full-industry-chain platform spanning from the research, development, and manufacturing of medical imaging equipment to professional medical imaging diagnostic services.

The transformation of the medical imaging industry and the implementation of tiered diagnosis and treatment have created development opportunities for independent medical imaging centers. Data shows that third-party independent imaging centers have been established and developed in the United States for over 30 years. Among approximately 7,000 imaging centers in the U.S., third-party independent imaging centers account for about 40% of the market, whereas they remain a nascent phenomenon in China.

The National Health and Family Planning Commission has recently issued policies such as the “Basic Standards and Management Specifications for Medical Imaging Diagnostic Centers (Trial)” and the “Interpretation of the Basic Standards and Management Specifications for Independently Established Medical Institutions, Including Medical Imaging Diagnostic Centers.” These policies explicitly state that “independently established medical institutions aim to alleviate, to a certain extent, the imbalance in resource allocation,” and “encourage medical imaging diagnostic centers to develop chain and group operations, establishing standardized and normalized management and service models.”

“"KaiPu Medical Imaging Diagnostic Center" is China's first third-party independent chain of medical imaging diagnostic centers specializing in CT, MRI, DR, ultrasound, ambulatory ECG, remote consultations, and second opinions for complex cases. The first four independent medical imaging diagnostic centers have officially commenced operations in Shenyang and Harbin, with subsequent expansion planned for cities in East China, South China, Central China, and other regions. The group has become one of the leading enterprises in China with the largest number of operational independent third-party imaging centers.

“KePu Medical Imaging Diagnostic Center” is fully committed to providing the general public with professional, convenient, and authoritative medical imaging examination and diagnostic services; building a bridge between patients and hospitals to serve as a valuable complement and collaborative partner for medical imaging examinations and diagnostics at hospitals of all levels; and establishing the authoritative “KePu Imaging Cloud,” a regional medical imaging diagnostic platform that enables remote consultations for primary healthcare institutions, thereby comprehensively enhancing the quality of medical imaging diagnosis and service standards at the grassroots level.

Since 2014, national policies have provided significantly greater support for medical imaging equipment than ever before, including guiding healthcare institutions to adopt domestically produced imaging devices, streamlining regulatory and approval processes to encourage innovation, and providing targeted financial subsidies. This policy-driven localization of medical imaging equipment will drive growth in China’s medical imaging equipment market size and rapidly increase the market share of domestic manufacturers in the short to medium term.

In Benxi, known as the “Pharmaceutical Capital of China,” Kaipu Imaging Group has established a technical team with global vision and independent R&D capabilities to carry out the research, development, and production of high-end medical equipment such as CT scanners. Dr. Zou Yu, the company’s Chief Scientist, earned his Ph.D. from the Institute of Physics, Chinese Academy of Sciences, and in the United StatesVanderbilt UniversityPostdoctoral Fellow, Postdoctoral Fellow at the University of Chicago, USA; formerly Distinguished Scientist at Toshiba America Research and Chief Scientist for Toshiba CT. He has been granted 34 U.S. patents and had 8 U.S. patent applications published while at the University of Chicago and Toshiba America Research.

Led by Dr. Yu Zou, Chief Scientist, the R&D team of over 100 members comprises returning overseas talents and industry key personnel, stationed at the company’s headquarters in China and its research center in the United States. Currently, this team has developed a series of high-end medical devices with independent intellectual property rights, including the Precision 32 Precision Tomographic Spectral CT, at a speed that has astonished the industry, rapidly propelling Kaipu Imaging Group into the ranks of China’s leading providers of independently innovated high-end medical equipment.

Precision32 Precision Tomographic Spectral CT is the first CT product independently developed by Kaipu Imaging Group. Currently, this product is in the clinical testing phase and is expected to officially enter the market early next year. Precision32 features the world’s exclusive Paxial precision tomography patented technology, the industry’s first 32-slice spectral imaging technology, and a powerful self-developed CPW imaging workstation. Its launch will set a new standard for Chinese-manufactured 32-slice CT systems.

Yueyin Medical Fund is widely recognized as one of the most professional healthcare investment firms in the industry. A review of its prior investments—including Meimu Ophthalmology, Blue Ocean Strategy, Zhenluo Technology, Genetron Health, Ruihua Kangyuan, Puernrui Biotechnology, Healthbound, Mingyi Zhudao, The Lancet Guest, and Shuchuang Robotics—demonstrates a consistent adherence to the same “focus on specialization” logic.

Regarding this round of investment in Kaipu Imaging Group, Ms. Zheng Yufen, CEO and Managing Partner of Joying Medical Fund, stated candidly: “In China, hospital revenue from medical imaging ranks second only to pharmaceuticals. The imaging market has already reached RMB 400 billion, and driven by multiple factors such as demand and policy, this hundred-billion-yuan market will continue to expand. We are delighted to partner with Kaipu Imaging Group. Its business model and R&D capabilities are at the forefront of the industry. Mr. Sun Zhaochang, the founder, has been deeply engaged in the medical imaging sector for over two decades, accumulating extensive industry experience and a proven track record in entrepreneurship. The founding team, led by Mr. Sun Zhaochang and Chief Scientist Dr. Zou Yu, is both pragmatic and passionate. We have full confidence in this team and are highly optimistic about our collaboration.”

The injection of capital will fuel the rapid growth of Cape Imaging Group, creating new momentum and opportunities. From this point forward, Cape Imaging Group is fully accelerating into a fast-track development model, which has the potential to reshape the competitive landscape of China’s healthcare industry.